Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Autologous Bone Marrow Mononuclear Cells in ALS
NCT02242071Phase 1Withdrawn
- Sponsor
- NeuroGen Brain & Spine Institute
- Start
- Dec 2008
- Primary completion
- Mar 2015
- Modality
- Stem Cell Therapies
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of autologous bone marrow-derived mononuclear cell in amyotrophic lateral sclerosis (ALS), sponsored by NeuroGen Brain & Spine Institute. Primary endpoint: Amyotrophic Lateral Sclerosis Functional Rating Scale-Revised at 2 years. Planned start Dec 2008; status: withdrawn.
02
Drugs
autologous bone marrow-derived mononuclear cell
03
Conditions
amyotrophic lateral sclerosis (ALS)
Beyond the preview
Go deeper on NCT02242071.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02242071.